Crucell and Toyobo sign research license agreement

Under the agreement, Toyobo Gene Analysis will evaluate Crucell’s Star technology for generating cell lines for the production of recombinant proteins for third-party customers. Financial details of the agreement were not disclosed.

Star technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell’s PER.C6 human cell technology and the widely used Chinese hamster ovary cell line.